PR Newswire Clinical TrialsOriginal article
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
Phase 2positiveABBV-466Positive
AI Analysis
Summary
AbbVie presented Phase 2a data showing ABBV-466, a novel dual-targeting therapy, achieved higher endoscopic remission rates than anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12 in moderate to severe Crohn's disease. The treatment difference between ABBV-466 and the monotherapy groups increased further at later timepoints.
Clinical Trial Data
Phase
Phase 2a
Primary Endpoint
Met
Outcome Details
In a Phase 2a study, ABBV-466 (dual-targeting anti-IL-23/anti-α4β7 therapy) achieved higher endoscopic remission rates than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint; the treatment difference further increased at later timepoints.
Importance:6/10
Sentiment:
0.70
Crohn's diseasePhase 2adual-targetinganti-IL-23anti-α4β7endoscopic remissioninflammatory bowel diseasedata presentation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 19, 2026 8:00 AM